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Genetically unstable tetraploid cells can promote
tumorigenesis. Recent estimates suggest that
37% of human tumors have undergone a genome-
doubling event during their development. This poten-
tially oncogenic effect of tetraploidy is countered
by a p53-dependent barrier to proliferation. However,
the cellular defects and corresponding signaling
pathways that trigger growth suppression in tetra-
ploid cells are not known. Here, we combine RNAi
screening and in vitro evolution approaches to
demonstrate that cytokinesis failure activates the
Hippo tumor suppressor pathway in cultured cells,
aswell as in naturally occurring tetraploidcells in vivo.
Induction of the Hippo pathway is triggered in part
by extra centrosomes, which alter small G protein
signaling and activate LATS2 kinase. LATS2 in turn
stabilizes p53 and inhibits the transcriptional regula-
tors YAP andTAZ. These findings define an important
tumor suppressionmechanismanduncover adaptive
mechanisms potentially available to nascent tumor
cells that bypass this inhibitory regulation.
INTRODUCTION
Proliferating tetraploid cells are genetically unstable and can
promote tumorigenesis (Davoli and de Lange, 2011, 2012; Fuji-
wara et al., 2005; Ganem et al., 2007). Accumulating evidence
points to a significant contribution of tetraploid intermediates
in shaping the composition of cancer genomes: 20% of all
solid tumors exhibit tetraploid or near-tetraploid karyotypes,
and computational analysis of human exome sequences from
4,000 human cancers reveals that 37% of all tumors, even
those with a near-diploid karyotype, have undergone at leastone whole-genome-doubling event at some point in their evolu-
tion (Dewhurst et al., 2014; Zack et al., 2013).
Potentially oncogenic tetraploid cells arise spontaneously
through a variety of different cell division errors. Defects in
mitosis and cytokinesis are thought to be the most common
routes; however, tetraploid cells also develop as a consequence
of viral-induced cell fusion, chromosome endoreduplication,
oncogene activation, chronic inflammation, entosis, and telo-
mere erosion (Davoli and de Lange, 2011; Ganem et al., 2007).
Importantly, tetraploid cells are capable of promoting trans-
formed growth irrespective of the mechanism by which they
were initially generated (Davoli and de Lange, 2012; Fujiwara
et al., 2005).
Given the potentially oncogenic consequences of tetraploidy,
it is not surprising that tumor suppression mechanisms have
evolved that limit the proliferation of these cells. Indeed, the
restrained growth of tetraploid cells has long been recognized;
it was first demonstrated in 1967 that inhibition of cytokinesis
in nontransformed cells severely impairs the proliferation of the
resulting binucleated tetraploids (Carter, 1967). Subsequently,
it became clear that p53 is the key mediator of this arrest (An-
dreassen et al., 2001; Ganem and Pellman, 2007; Kuffer et al.,
2013; Wright and Hayflick, 1972). However, the defect(s) that
triggers this stress response and the downstream signaling path-
ways that activate p53 remain key unresolved questions in can-
cer biology. Consequently, the mechanisms by which tetraploid
cells might bypass this response to drive tumor development are
not known.
We took two approaches to understand themechanism of p53
activation in tetraploid cells. First, we performed RNAi screens to
identify genes that are required to activate or maintain cell-cycle
arrest in tetraploid cells, but not cells with DNA damage. Second,
we carried out in vitro evolution experiments to identify sponta-
neous adaptations that enable sustained proliferation of tetra-
ploid cells. Our experiments demonstrate that the impaired
proliferation of tetraploid cells is due to activation of the Hippo
tumor suppressor pathway both in vitro and in vivo.Cell 158, 833–848, August 14, 2014 ª2014 Elsevier Inc. 833
The conserved Hippo tumor suppressor pathway regulates
cell proliferation by negatively regulating the oncogenic tran-
scriptional coactivators YAP and TAZ (Pan, 2010; Yu and
Guan, 2013). This is primarily accomplished through activation
of the kinases LATS1 and LATS2, which phosphorylate and inac-
tivate YAP/TAZ. Active LATS2 also binds to and inhibits the E3
ubiquitin ligase MDM2, which normally targets p53 for destruc-
tion (Aylon et al., 2006). Thus, activation of the Hippo pathway
can limit cellular proliferation in at least two ways: inactivating
YAP/TAZ and stabilizing p53.
Defining the inputs that initiate Hippo signaling is central to un-
derstanding how the Hippo pathway restrains tumorigenesis.
Recent studies have demonstrated that the Hippo pathway is
regulated by complex inputs that monitor cell-cell adhesion,
cell-matrix adhesion, and contractile tension from the actin cyto-
skeleton. The molecular details of these upstream signals, espe-
cially those from the actin cytoskeleton, are poorly understood
(Halder et al., 2012). Here, we demonstrate that cytokinesis fail-
ure, generating tetraploid cells, is another physiological activator
of the Hippo pathway, and we provide mechanistic insight into
this important tumor suppression mechanism.
RESULTS
Tetraploid Cells Activate the p53 Pathway
We developed a method to purify tetraploid cells as a prerequi-
site for an RNAi screen to identify the genes required for the p53-
dependent G1 cell-cycle arrest following cytokinesis failure. We
used RPE-1 cells, which are diploid nontransformed human
epithelial cells that maintain a normal p53-response. To generate
tetraploid cells, RPE-1 cells were treated with dihydrocytochala-
sin B (DCB), an inhibitor of actin polymerization that prevents
cytokinesis. However, separating the resulting binucleated tetra-
ploids from the remaining diploids poses a technical challenge
because the two populations cannot be distinguished by DNA
content alone: diploid cells in G2/M have the same DNA con-
tent (4C) as tetraploid cells arrested G1. We overcame this diffi-
culty by combining DNA content analysis with the fluorescent
ubiquitin-based cell cycle indicator (FUCCI) reporter system.
FUCCI consists of two fluorescent proteins whose expression
alternates based on cell-cycle position: hCdt1-mCherry is ex-
pressed in G1, whereas hGem-Azami Green is expressed in
S/G2/M (Sakaue-Sawano et al., 2008). Using this approach, we
could efficiently separate G2/M diploids (green) from G1 tetra-
ploids (red) and were able to isolate 95% pure G1 tetraploid
cells.
Using the RPE-FUCCI cell line, we assessed p53 levels in
tetraploid cells relative to diploids. Levels of p53 (and its target
p21) gradually increased in tetraploids to 2.5-fold over diploid
levels by 48 hr after cytokinesis failure (Figures 1A, 1B, S1A,
and S1B available online). To examine the consequences of
this p53 accumulation on cell-cycle progression, live-cell imag-
ing of diploid and tetraploid FUCCI cells was performed. Imaging
revealed that 97.3% of G1 diploids entered S phase and divided,
usually within 24–36 hr of replating (Figure 1C and Movie S1). By
contrast, only 14.3% of tetraploid cells entered S phase within
4 days; the majority remained arrested in G1 until they became
senescent (Figures 1C and S1C and Movie S2). The rare tetra-834 Cell 158, 833–848, August 14, 2014 ª2014 Elsevier Inc.ploid cells that did progress through the cell cycle and complete
mitosis predominantly arrested in the following G1 phase, as pre-
viously documented (Krzywicka-Racka and Sluder, 2011; Kuffer
et al., 2013). Depletion of p53 enabled 95.1% of tetraploid cells
to enter S phase (Figure 1C and Movie S3), confirming that the
tetraploid arrest is p53 dependent. Similar results were observed
when cells were made tetraploid through cytokinesis failure
induced by either small interfering RNA (siRNA)-mediated
depletion of ECT2 or by treatment with the Aurora B inhibitor
Hesperidin (Figure S1E). These data suggest that tetraploidiza-
tion caused by cytokinesis failure imposes a stress on cells
that leads to the stabilization of p53 and eventual G1 arrest.
Consistent with previous studies (Fujiwara et al., 2005; Krzy-
wicka-Racka and Sluder, 2011), our findings exclude subtle
DNA damage as the underlying cause for G1 arrest in tetraploid
cells: (1) Diploid cells exposed to the same cell culture condi-
tions, drug treatments, and FACS sorting procedures as tetra-
ploid cells did not trigger G1 arrest (Figure 1C). (2) No increase
in DNA damage or reactive oxygen species was observed in
tetraploid cells (Figure S1F), and the antioxidant N-acetylcys-
teine was unable to overcome tetraploid-induced arrest (Fig-
ure S1D). (3) Tetraploid cells failed to enter S phase even after
14 days in culture, which is ample time for DNA repair (Fig-
ure S1C). (4) Tetraploid cells depleted of p53 not only progressed
throughG1/S but also throughG2/M, strongly arguing against the
presence of persistent DNA damage, which would activate p53-
independent G2 arrest (as is seen in p53-depleted cells after
doxorubicin treatment; Figure 2C). (5) Inhibition of ATM kinase
was insufficient to overcome tetraploid-induced arrest, despite
the fact that it was sufficient to overcome DNA damage-induced
arrest caused by low-dose doxorubicin treatment (which ele-
vates p53/p21 protein levels to a similar extent as tetraploidiza-
tion) (Figures 1D and 1E). (6) Finally, below we describe genetic
conditions permissive for tetraploid cells, but not cells with DNA
damage, to continue proliferating (and vice versa), demon-
strating that these arrestmechanisms are fundamentally distinct.
A Genome-wide RNAi Screen to Identify Regulators of
Tetraploid-Induced Cell-Cycle Arrest
We performed an RNAi screen to identify the genes required
for tetraploid-induced G1 cell-cycle arrest using pooled siRNAs
targeting the druggable portion of the human genome (7,300
genes). Automated image analysis measured the total number
of tetraploid cells per well and the percentage that emitted green
fluorescence (indicative of S/G2/M and proliferation) at 96 hr
posttransfection (Figure 1F).
The screen identified 98 proteins for which depletion with at
least two individual siRNAs allowed tetraploid cells to escape
G1 arrest (Table S1): two of the strongest hits identified from
this screen were p53 and p21, validating the overall approach.
Genome-wide enrichment of seed sequence matches (GESS)
analysis of all siRNA sequences that released tetraploid cells
from arrest revealed no common 30 UTR region, reducing the
possibility of a common off-target gene (Sigoillot et al., 2012).
Although the primary objective of the tetraploid screen was to
uncover genes that are necessary to activate or maintain tetra-
ploid-induced cell-cycle arrest, we anticipated that many of the
candidates we identified would also have roles in the general
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Figure 1. Genes that Mediate Cell-Cycle Arrest of Tetraploid Cells
(A) Western blot of p53 levels in diploid (2N) and tetraploid (4N) cells 48 hr after sorting (n = 6; *p < 0.001, unpaired t test).
(B) Diploid (arrowhead) and binucleated tetraploid (arrow) cells stained for p53 (green), p21 (yellow), actin (red), and DNA (blue). Scale bar, 25 mm.
(C) Still images of sorted diploid and tetraploid RPE-FUCCI cells that were transfected with the indicated siRNAs (from a live-cell imaging experiment).
The percentage of cells that progress into S phase from five independent imaging experiments is shown on right (2N, n = 119; 4N, n = 326; 4N p53 siRNA, n = 211;
*p < 0.00001, unpaired t test). Time, hr:min. Scale bar, 100 mm.
(D) The fraction of S/G2 cells from 2N and tetraploid 4N cells following treatment with ± 25 ng/ml doxorubicin and ± 10 mMATM inhibitor for 24 hr (n = 3; *p < 0.05,
unpaired t test, n.s., not significant).
(E) Representative images of FUCCI cells from the experiment in (D). Scale bar, 100 mm.
(F) Protocol for genome-wide RNAi screen to identify genes necessary to activate or maintain G1 cell-cycle arrest in tetraploid cells after cytokinesis failure.
All error bars represent mean ± SEM.
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maintenance of p53-induced cell-cycle arrest, independent of
tetraploidy. To distinguish between these two broad classes of
genes, we performed a second genome-wide screen to identify
genes that, when suppressed, enable cells to bypass G1 arrest in
response to low-level DNA damage. This screen was similar
in design to the tetraploid screen detailed above, except that,
instead of cells being treated with DCB to create tetraploids,
they were continuously treated with 40 ng/ml of the DNA-
damaging drug doxorubicin, which elevates p53 and p21 levels
to a similar extent as cytokinesis failure (Figures S2A and 4C).
A comparison of the results from the tetraploid screen with the
DNA damage screen identified three classes of gene knock-
downs (Figures 2A–2C): (1) those that allow cells with DNA dam-
age (but not tetraploid cells) to progress into S phase, suggesting
a specific role for the encoded proteins in the DNA damage
response (e.g., ataxia telangiectasia mutated, ATM) (Table S2).
These factors were not further characterized in this study. (2)
Knockdowns that enable both tetraploid cells, as well as cells
with DNA damage, to progress into S phase, implying a role for
the encoded proteins in the general maintenance of cell-cycle ar-
rest upon p53 activation (e.g., p21). (3) Knockdowns that allow
tetraploid cells (but not cells with DNA damage) to progress
into S phase, implying a role for the encoded proteins in acti-
vating or maintaining G1 arrest specifically in the context of tetra-
ploidy (e.g., LATS2).
Hyperactivation of Growth Factor Signaling Is a General
Mechanism to Bypass Tetraploid-Induced Arrest
We expected that our screens might identify genes that are
generally required to activate p53. To test this, we assessed
p53/p21 levels following siRNA knockdown of several strong
screen hits. Surprisingly, depletion of most genes did not reduce
p53/p21 levels, demonstrating that cell proliferation can occur
via mechanisms that bypass p53 activation rather than sup-
pressing it (Figure 2D).
Interestingly, many strong hits from the screen (e.g., SPINT2)
are putative negative regulators of growth factor signaling (Naka-
mura et al., 2011), suggesting that sustained growth factor
signaling may be one route to overcome p53 cell-cycle arrest.
We measured the kinetics of ERK1/2 and AKT activation after
serum addition to serum-starved cells and confirmed that deple-
tion of our strongest hit, SPINT2, causes a sustained increase in
growth factor signaling (Figures 2E and S2B). We also found that
increasing the concentration of serum or adding recombinant
IGF-1 alone was sufficient to overcome G1 arrest in tetraploidFigure 2. Enhanced Growth Factor Signaling Overcomes p53-Induced
(A) Venn diagram depicting genes necessary to maintain G1 arrest in response to
(B) Representative images of G1-arrested diploid RPE-FUCCI cells treated ± 40 n
row) transfected with the indicated siRNAs. Scale bar, 50 mm.
(C) Quantification of the percentage of S/G2 from (B) (n = 3; *p < 0.002, unpaired
(D) Western blot of p53 and p21 protein levels in 2N and 4N cells transfected wit
(E) A representative western blot (and quantitation) of phosphorylated AKT (p-AKT
cells that were transfected with the indicated siRNAs.
(F) The percentage of S/G2 tetraploid RPE-FUCCI cells in growth medium conta
(n = 48 for each condition). Right: representative images from a live-cell experim
(G) The percentage of S/G2 tetraploid RPE-FUCCI cells in growthmedium supplem
*p < 0.0005, unpaired t test).
All error bars represent mean ± SEM.cells (Figures 2F and 2G). Thus, one general mechanism for
bypassing p53-dependent cell-cycle arrest of tetraploid cells is
to activate growth factor signaling; this suggests that other hits
identified from the screen might therefore represent uncharac-
terized negative regulators of growth factor signaling. In fact,
we found that depletion of the RNA-binding protein PTBP1,
one of the strongest hits from the screen, similarly increased
growth factor signaling (Figures 2E and S2B).
Tetraploid Cells Activate the Hippo Pathway
We next focused on genes that activated or maintained G1 arrest
specifically in the context of tetraploidy. The strongest ploidy-
specific hit was the kinase LATS2, a core component of the Hip-
po tumor suppressor pathway (Pan, 2010; Yu and Guan, 2013).
We confirmed that depletion of LATS2 with five independent
siRNAs, targeting both the coding and UTR regions of LATS2
mRNA, enabled the proliferation of tetraploid cells, but not cells
with DNA damage (Figures 3A, 3B, and S3A–S3C). Depletion of
LATS2 similarly promoted the proliferation of tetraploid cells
generated by siRNA depletion of the cytokinesis regulators
ECT2 and PRC1 (Figure S3D). Importantly, expression of
siRNA-resistant wild-type LATS2 in proliferating tetraploid cells
that were depleted of endogenous LATS2 was sufficient to
rescue cell-cycle arrest, confirming that the effect of LATS2
depletion is not due to off-target RNAi effects (Figure 3C). By
contrast, expression of kinase-dead LATS2 failed to rescue, indi-
cating that the arrest mechanism requires the kinase activity of
LATS2 (Figure 3C). Depletion of LATS1 kinase, which is highly
homologous to LATS2 and has many overlapping functions,
was not sufficient to enable the proliferation of tetraploids (Fig-
ure 3A); however, codepletion of both LATS1 and LATS2 pro-
duced a small increase in the rate of proliferation of tetraploid
cells relative to LATS2 depletion alone (Figure S3C).
These data suggested that G1 arrest in tetraploids requires
LATS2 activation. Indeed, LATS2was phosphorylated to a signif-
icantly greater extent in tetraploid cells (Figure 3D), which led to a
corresponding increase in the level of phosphorylated YAP in
tetraploid cells relative to diploids (Figures 3E, S3E, and S3H).
We also found that YAP was biased to be cytoplasmic (inactive)
in tetraploid cells, in contrast to its primarily nuclear (active) local-
ization in diploid cells (Figure 3F). This finding was independently
verified in tetraploid cells that were generated by use of ECT2
siRNA (Figure S3F). In addition, levels of the YAP-related tran-
scriptional coactivator TAZ, which is proteasomally degraded
upon phosphorylation by active LATS, were significantlyG1 Arrest
low-level DNA damage (gray), tetraploidization (red), or both.
g/ml doxorubicin (top row) and untreated tetraploid RPE-FUCCI cells (bottom
t test).
h the indicated siRNAs for 48 hr.
) relative to total AKT at various time points following serum addition to starved
ining increasing concentrations of serum from one representative experiment
ent. Scale bar, 50 mm.
entedwith 50 ng/ml IGF-1 or IGF-1 and theMEK inhibitor U0126 (10 nM) (n = 3;
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Figure 3. Tetraploid Cells Activate the Hippo Pathway
(A) The percentage of S/G2 tetraploid RPE-FUCCI cells following transfection with the indicated siRNAs (n = 4; *p < 0.0001, unpaired t test). Representative
images from (A) are on the right. Scale bar, 100 mm.
(B) As in (A), except cells are treated with 40 ng/ml doxorubicin (n = 3; *p < 0.0001, unpaired t test).
(C) The percentage of S/G2 tetraploid RPE-FUCCI cells stably expressing wild-type LATS2 (LATS2-WT), kinase-dead LATS2 (LATS2-KD), or empty vector control
(control) and transfected with the indicated siRNAs (n = 3; *p < 0.007, unpaired t test).
(D) Western blot analysis and quantitation of LATS phosphorylation in 2N and 4N cells (n = 3; *p < 0.009, unpaired t test). Note: cells stably overexpressing LATS2
were used in this experiment to better assess LATS2 phosphorylation.
(E) Western blot analysis and quantitation of YAP phosphorylation (S127) in 2N and 4N cells (n = 3; *p < 0.008, unpaired t test).
(legend continued on next page)
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decreased in tetraploid cells (Figure 3G). Furthermore, canonical
YAP/TAZ target genes had reduced expression in tetraploid cells
(Figure 3H). This differential activation of Hippo signaling be-
tween diploids and tetraploids is not due to subtle differences
in cell-cycle position because diploid and tetraploid cells syn-
chronized in G1 by release from serum starvation displayed the
same changes (Figures S3G and S3H). Hippo activation in tetra-
ploids is also not a secondary consequence of p53 activation
(Aylon et al., 2006), as depletion of p53 did not prevent Hippo
activation in tetraploid cells (Figure S3I). Thus, LATS2-mediated
Hippo signaling is selectively activated in tetraploid cells.
Next, we characterized the mechanisms through which deple-
tion of LATS2 overcomes tetraploid-induced arrest. As ex-
pected, depletion of LATS2 activated YAP, as demonstrated
by a decrease in YAP phosphorylation and an accumulation of
nuclear YAP (Figures 4A and S4A). Moreover, overexpression
of a constitutively active mutant version of YAP (with all of the
LATS phosphorylation sites mutated to alanines: YAP-S5A)
released tetraploid cells into the cell cycle, irrespective of
whether they were generated by DCB treatment or siRNA-medi-
ated knockdown of ECT2 or PRC1. Importantly, expression of
constitutively active YAP-S5A restored proliferation to tetraploid
cells without affecting the steady-state levels of p53 (Figures 4B
and S4B–S4D). By contrast, overexpression of WT-YAP alone
was insufficient to drive tetraploid cells into the cell cycle, pre-
sumably because of the ability of endogenous LATS kinases to
phosphorylate and inactivate WT-YAP.
Next, we examined whether active LATS2 contributes to the
observed increase in p53 levels in tetraploid cells. We found
that depletion of LATS2 from tetraploid cells restored p53 to
the basal levels observed in diploid cells (Figure 4C). By contrast,
depletion of LATS1 had no effect (Figure S4E), explaining
why depletion of LATS1 alone was insufficient to promote tetra-
ploid proliferation (Figures 3A and S3A). Although depletion of
LATS2 reduced p53 levels in tetraploid cells, the kinase had no
effect on the accumulation of p53 in cells with DNA damage (Fig-
ure 4C). These data establish that themechanism underlying p53
stabilization and cell-cycle arrest in tetraploid cells is LATS2
dependent but is functionally distinct from that used to activate
p53 in cells with DNA damage.
Active LATS2 binds and inhibits the E3 ubiquitin ligase MDM2,
which targets p53 for destruction, thereby indirectly leading to
the stabilization of p53 (Aylon et al., 2006). We found that
LATS2 interacted with MDM2 in tetraploid, but not diploid, cells
(Figure 4D), similar to what had been previously observed in
tetraploid cells generated from mitotic slippage (Aylon et al.,
2006). Collectively, these findings demonstrate that activation
of LATS2 in tetraploid cells inactivates YAP and stabilizes p53.
Tetraploid Cells Have Reduced RhoA Activity
We sought to understand the mechanisms leading to LATS2
activation in tetraploid cells. Canonically, the kinases MST1(F) Diploid (arrowhead) and binucleated tetraploid (arrow) RPE-1 cells stained for Y
evenly distributed; N < C, YAP is enriched in the cytoplasm; N > C, YAP is enrich
(G) Western blot analysis and quantitation of TAZ levels in 2N and 4N RPE-FUCC
(H) qPCR analysis of YAP target gene expression in 2N and 4N cells (n = 3; *p <
All error bars represent mean ± SEM.and MST2 act directly upstream of LATS2 in Hippo pathway
signaling; however, we found that codepletion of MST1/2 did
not trigger the proliferation of tetraploids, demonstrating that
the tetraploid-induced activation of LATS2 is MST1/2 indepen-
dent (Figure S4F). Recent work shows that reduced assembly
or contractility of the actin cytoskeleton or reduced RhoA activity
can activate LATS1/2 independent of MST1/2 (Mo et al., 2012;
Wada et al., 2011; Yu et al., 2012; Zhao et al., 2012). The cyto-
skeleton of tetraploid cells is qualitatively different from that of
diploid cells: tetraploid cells are bigger, possess longer stress
fibers, and have extra centrosomes that cluster together and
nucleate a greater number of microtubules (Figure S4G). How-
ever, they do not exhibit obvious defects in cell attachment,
migration, or cell spreading (Movie S2). Nevertheless, we found
that active RhoA was reduced by 50% in tetraploid cells
compared to diploids (Figure 4E), which correlates well with a
comparable decrease in downstream phosphorylation of myosin
light chain (Figure S4H).
The biological impact of this reduction of RhoA activity was as-
sessed using two independent approaches. First, we compared
the contractility of diploid and tetraploid cells using traction force
microscopy. A mix of diploid and tetraploid RPE-1 cells was
plated on deformable polyacrylamide hydrogels coated with
fibronectin. Gel deformation induced by the contraction of cells
was then monitored to measure the forces produced. This anal-
ysis demonstrated that, relative to their size, tetraploid cells ex-
erted significantly reduced contractile force on the underlying
substrate than diploids (Figures 4F, S5A, and S5B). We also
employed a commonly used indirect assay for the tensile state
of cells, the differentiation of human mesenchymal stem cells
(hMSCs) (McBeath et al., 2004). When hMSCs have high RhoA
activity and are more contractile, which occurs when these cells
are plated at low density on stiff substrates, hMSCs activate YAP
and primarily differentiate into osteoblasts. By contrast, when
RhoA activity is low, which occurs when cells are contact in-
hibited, hMSCs exhibit less YAP activation and more frequently
differentiate into adipocytes. Supporting our finding that tetra-
ploids have less active Rho, we found that, when isogenic diploid
and tetraploid hMSCs were plated in mixed differentiation
medium at low densities, tetraploid cells significantly more
frequently differentiated into adipocytes (Figure 4G).
Finally, reactivation of RhoA was sufficient to inactivate the
Hippo pathway, reduce p53 levels, and restore proliferative ca-
pacity to tetraploid cells (Figure 4H). Treatment of G1-arrested
tetraploid cells with LPA or S1P (glycophospholipids known to
activate RhoA) (Miller et al., 2012; Yu et al., 2012) significantly
increased the fraction of tetraploid cells that entered the cell
cycle (Figure S5C), as did induced expression of RhoA-WT or
constitutively active RhoA-Q61L (Figure 4H). Importantly, neither
of these conditions had any effect on the G1 arrest imposed
by low-level DNA damage (Figures 4H and S5D). These data
demonstrate that tetraploid cells have reduced RhoA activity,AP (green) and DNA (blue). YAP localization was quantified (n = 2; N =C, YAP is
ed in nucleus). Scale bar, 25 mm.
I cells (n = 4; *p < 0.005, one sample t test).
0.02 and **p < 0.005, one sample t test).
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Figure 4. LATS2 Inhibits the Proliferation of Tetraploid Cells by Stabilizing p53 and Inactivating YAP and Is Triggered by Reduced RhoA
Activity
(A) Western blot of p53, LATS2, and active YAP (p-S127) levels in 2N and 4N cells transfected with the indicated siRNAs.
(B) Representative images of 2N and 4N RPE-FUCCI cells overexpressing either empty vector control (control), YAP-WT, or YAP-S5A, with quantitation of the
percentage of S/G2 cells for each condition shown on the right (from one representative experiment). Scale bar, 100 mm.
(C) Western blot analysis of p53 and LATS2 levels in 2N, 4N, and 40 ng/ml doxorubicin-treated 2N (2N +Dox) RPE-FUCCI cells transfected with the indicated
siRNAs.
(D) Coimmunoprecipitation of HA-tagged LATS2-WT and endogenous MDM2 from 2N and 4N RPE-1 cells using anti-HA antibodies (one of two independent
experiments).
(legend continued on next page)
840 Cell 158, 833–848, August 14, 2014 ª2014 Elsevier Inc.
which triggers LATS2 activation and stalls the cell cycle by acti-
vating p53 and inactivating YAP.
Extra Centrosomes Promote Activation of the Hippo
Pathway
We sought to define the upstream trigger for RhoA suppression
and LATS2 activation in tetraploid cells. One of the most obvious
differences between diploid and tetraploid cells lies in the num-
ber of centrosomes they each possess: diploid cells have one
centrosome during G1 phase, whereas tetraploid cells have
two. Consequently, tetraploid cells have an increased number
of centrosomal microtubules (Figure S4G). Independent work in
our laboratory has revealed that extra centrosomes increase
centrosomal microtubule assembly and stimulate the activity of
the small G protein Rac1 (Godinho et al., 2014). Rac1 activation
by microtubules was previously described (Waterman-Storer
et al., 1999), and this activation appears to require dynamic mi-
crotubules because it is suppressed by Taxol-induced microtu-
bule stabilization. Because active Rac1 often antagonizes RhoA
(Sander et al., 1999), we tested the possibility that the extra
centrosomesof tetraploid cellsmaymediateHippopathway acti-
vation via microtubule-dependent hyperactivation of Rac1. We
measured the relative levels of active Rac1 in diploids and tetra-
ploids and found a nearly 2-fold increase in Rac1 activity in tetra-
ploids (Figure 5A). This increase in active Rac1 is functionally
significant, as quenching hyperactivation of Rac activity in G1-
arrested tetraploids through siRNA depletion or pharmacological
inhibition was sufficient to inactivate Hippo signaling and reduce
p53 levels (Figures 5B, 5C, and S5E). Although complete deple-
tion of Rac1 is known to inhibit cyclin D accumulation and halt
proliferation (Figure 5B), we found that graded attenuation of
Rac activity with partial siRNA knockdown or low-dose drug
treatment could enable tetraploid cells to proliferate (Figures
5B, 5C, and S5E). Strikingly, we found that Taxol treatment of
cells also inhibited Rac activation, prevented Hippo activation
and p53 accumulation, and enabled cells to override tetraploid-
induced G1 arrest (Figure 5D). By contrast, inactivation of Rac
had no effect onG1 arrest imposed byDNAdamage (Figure S5F).
These data suggested that the extra centrosome present in
tetraploid cells is one trigger for Hippo pathway activation. To
test this, we induced extra centrosomes in diploid RPE-1 cells
by transient overexpression of PLK4 kinase (a key regulator of
centriole biogenesis) and thenmeasured Hippo pathway activity.
As expected, PLK4 overexpression led to the formation of extra
centrosomes in 60%–80% of cells after 48 hr, and these cells
showed subtle activation of the Hippo pathway as judged by in-
creases in the phosphorylation of LATS2 and YAP (Figure 5E). As(E) Western blot analysis and quantitation of pull-down assays to detect active
*p < 0.0003, one sample t test).
(F) Top row: 2N, 4N, and evolved 4N RPE-1 cells labeled for actin (Lifeact, white) a
corresponding to the upper cells. The size and color of the arrows correspond t
density generated by each cell. 2N and 4N data points are from four independen
*p < 0.0001, unpaired t test. Scale bar, 20 mm.
(G) hMSCs grown in mixed differentiation medium and stained with oil red. A non
highlighted. Right: the percentage of diploid and binucleated tetraploid cells tha
(H) The percentage of S/G2 tetraploid or doxorubicin-treated RPE-FUCCI cells ±
with the corresponding western blot analysis of Hippo pathway activation (n = 3
All error bars represent mean ± SEM.previously reported, these cells also exhibited elevated levels of
p53 and proliferated slowly (Figure 5E) (Holland et al., 2012). In
common with what was observed in tetraploid cells, depletion
of LATS2 significantly diminished Hippo pathway activation
and p53 levels in PLK4-overexpressing cells (Figure 5E). These
results indicate that the Hippo pathway activation observed in
tetraploids is initiated, at least in part, by the effects of extra
centrosomes.
Tetraploid Hepatocytes Activate the Hippo Pathway
In Vivo
To determine whether spontaneously arising tetraploid cells acti-
vate the Hippo pathway and exhibit reduced proliferation in vivo,
we focused on the developing murine liver: hepatocytes of
newbornmice are initially diploid but becomeprogressively tetra-
ploidwithageviaprogrammedcytokinesis failure (Duncan, 2013).
We found that the proliferation of tetraploid hepatocytes was in-
hibited, but not abolished, as evidencedby a significant reduction
in the incorporation of EdU that was injected into 3-week-old
animals (Figure 6A). We also confirmed a requirement for p53
in this growth limitation: EdU incorporation in tetraploid hepato-
cytes was significantly increased in p53/mice (Figure 6B) (Kur-
inna et al., 2013). Furthermore, tetraploid hepatocytes showed
increased levels of p53 and p21 relative to diploids (Figure 6C).
Our experiments also indicated that primary tetraploid hepa-
tocytes activate the Hippo pathway, as judged by increases in
phosphorylated LATS and YAP in tetraploid hepatocytes relative
to diploids (Figure 6C). Moreover, we performed gene expres-
sion analysis on primary diploid and tetraploid hepatocytes,
and gene-set enrichment analysis (GSEA) indicated that tetra-
ploid hepatocytes displayed significant repression of hepato-
cyte-specific YAP target genes relative to diploids (Figure 6D
and Figures S6A and S6B). To address whether restoring YAP
activity is sufficient to promote tetraploid-hepatocyte prolifera-
tion in vivo, doxycycline-inducible YAP S127A (a constitutively
active version of YAP) was expressed in the livers of 3-week-
old mice for 7 days. FACS analysis revealed that expression
of active YAP (identified by expression of a YFP fluorescence
reporter; Figure S6C) enhanced the proliferation of tetraploid
hepatocytes in vivo, as evidenced by a marked increase in cell
ploidy (Figure 6E). These data demonstrate that the Hippo
pathway restrains the growth of tetraploid cells in vivo.
Evolution Experiments Identify Adaptive Mechanisms of
Proliferating Tetraploid Cells
Our data suggest that proliferation of tetraploid cells can
be accomplished via direct inactivation the Hippo pathway, orRhoA relative to total RhoA in serum-starved, 2N, and 4N RPE-1 cells (n = 4;
nd DNA (blue) on a PAA hydrogel. Bottom row: images showing the force field
o traction force magnitude measured (in Pascals). Below: the average energy
t experiments; 4N evolved data points are from two independent experiments;
differentiated diploid hMSC (arrowhead) and a tetraploid adipocyte (arrow) are
t differentiate into adipocytes (n = two independent experiments).
induction of RhoA-WT, RhoA-Q61L, or empty vector control (control) for 20 hr
; *p < 0.005, unpaired t test).
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Figure 5. Increased Rac Activity Triggered by Extra Centrosomes Activates the Hippo Pathway
(A) Western blot analysis and quantitation of pull-down assays to measure active Rac1 relative to total Rac1 in serum-starved, 2N, and 4N RPE-1 cells (n = 5;
*p < 0.003, one sample t test).
(B–D) The percentage of S/G2 tetraploid RPE-FUCCI cells following siRNA-mediated depletion of Rac1 (B), ± 5 mM treatment with the Rac inhibitors NSC2376 and
EHT1864 (C), or 10 nM treatment with Taxol (D), along with corresponding western blot analysis of Hippo pathway activation (nR 3; *p < 0.01, unpaired t test).
(E) Western blot analysis (left) and quantitation (right) of Hippo activity and p53 levels in RPE-1 cells with or without transient doxycycline-induced PLK4 over-
expression and extra centrosomes. Cells were treated with control or LATS2 siRNAs prior to doxycycline treatment (n = 10; *p < 0.01, unpaired t test).
Error bars represent mean ± SEM.
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alternatively, by hyperactivation of growth factor signaling. As
an orthogonal approach to uncover pathways that can overcome
the block to proliferation of tetraploids, we performed an in vitro
evolution experiment: we generated a large number (1 3 108)
of tetraploid RPE-1 cells and FACS isolated the rare tetraploid
cells that were capable of re-entering the cell cycle (as indicated
by an 8C DNA content). As expected, the majority of these tetra-
ploids did not proliferate. Repeated FACS sorting was then
used to isolate a pure population of actively dividing tetraploid
cells. These ‘‘evolved tetraploids’’ were chromosomally stable,
and karyotypic analysis showed that they predominantly
possessed 92 chromosomes, with only a subset of cells
carrying a gain of chromosome 12. This chromosome stability
is likely due to the selection for tetraploid cells that lost their su-
pernumerary centrosomes and that maintain relatively balanced
gene expression (Ganem et al., 2009).
The evolved tetraploids exhibited reduced levels of p53 and
p21 as compared to freshly prepared tetraploids, despite the
fact that the p53 pathway remained functional in these cells
(Figures 7A and S7B). Gene expression profiling was used to
compare evolved tetraploids with the diploids from which they
were originally derived in order to uncover adaptations that the
evolved cells may have acquired to bypass the proliferative
block. Remarkably, of the 98 genes identified as hits from
the siRNA screen, 20 (including LATS2) were repressed in
the evolved tetraploids (Figures 7B and 7C). Indeed, GSEA
confirmed that, as a group, hits from the RNAi screenwere signif-
icantly downregulated in the evolved tetraploids (Figure 7B).
Because the proliferating tetraploids arose spontaneously, plas-
ticity in gene expression programsmay enable rare cells to over-
come the p53 activation triggered by tetraploidy.
Finally, we found that the evolved tetraploids inactivated the
Hippo pathway, as judged by a decrease in phosphorylated
YAP, restoration of YAP nuclear localization, and a correspond-
ing increase in the expression of YAP target genes (Figures 7A,
7D, and S7A). This is likely due, at least in part, to both reduced
level of LATS2 expression (Figure 7C) and loss of the additional
centrosome. Indeed, evolved tetraploids with a normal number
of centrosomes exhibited normal contractility by traction force
microscopy, suggesting restoration of normal Rac and Rho
function (Figures 4F, and S5A, and S5B). These data provide
an independent confirmation of the importance of silencing
Hippo signaling to enable proliferation of tetraploid cells.
DISCUSSION
Spontaneously arising tetraploid cells that result from nonprog-
rammed mitotic failures pose a serious threat to organismal
health because proliferating tetraploid cells are genomically
unstable and can facilitate tumor development (Davoli and de
Lange, 2011; Ganem et al., 2007). Tumor suppression mecha-
nisms appear to have evolved to neutralize potential risks asso-
ciated with tetraploidy (Ganem and Pellman, 2007; Senovilla
et al., 2012). However, the mechanisms that sense tetraploidiza-
tion and trigger p53 pathway activation have been poorly defined
and are controversial.
Early studies that used drug treatments to induce cytokinesis
failure found that tetraploid, but not diploid, cells within the samepopulation displayed a near complete loss of cell proliferation, a
finding that led to the proposed existence of a tetraploidy check-
point (Andreassen et al., 2001; Carter, 1967). However, subse-
quent work documented that G1 arrest is not an obligatory
outcome of tetraploidization and that, when tetraploid cells are
maintained under ideal tissue culture conditions, a significant
fraction of cells can re-enter the cell cycle (Uetake and Sluder,
2004; Wong and Stearns, 2005). The data we present here can
reconcile this apparent discrepancy—we show that tetraploid-
ization does not impose a requisite cell cycle block but rather
initiates a gradually accumulating p53 response (Figure S1B),
which only manifests as a G1 arrest once p53 levels induce suf-
ficient p21 to cross a critical threshold that is necessary to inhibit
S phase entry. Accordingly, conditions that prolong G1 phase in
tetraploid cells, and thus provide more time for p53/p21 to accu-
mulate, are more efficient at promoting an immediate cell-cycle
arrest. The gradual accumulation of stress, which ultimately trig-
gers cell-cycle arrest in tetraploids, is very similar to the arrest
observed in cells with extra centrosomes (Holland et al., 2012).
We demonstrate that the Hippo tumor suppressor pathway
has a central role in limiting the proliferation of tetraploid cells,
both in vitro and in vivo. We show that tetraploid cells activate
LATS2 kinase, inactivate YAP/TAZ-dependent transcription,
and stabilize p53 (Figure 7E). Our data are consistent with prior
work showing that LATS2 is required for cell-cycle arrest after
mitotic slippage (Aylon et al., 2006). These data confirm that
tetraploidy imposes stress on cells and suggest that the
development of high-ploidy tumors requires that cells adapt to
overcome or bypass these inherent limitations to growth.
Defects that Activate the Hippo Pathway in Tetraploid
Cells
A number of recent studies demonstrate that mechanical forces
generated by the actomyosin cytoskeleton have a major role in
regulating YAP/TAZ through both LATS-dependent and -inde-
pendent pathways (Aragona et al., 2013; Dupont et al., 2011;
Halder et al., 2012; Mana-Capelli et al., 2014; Mo et al., 2012;
Wada et al., 2011; Yu et al., 2012). Although the mechanisms
that link the contractility of the actin cytoskeleton to YAP activity
remain unknown, it is clear that RhoA plays a key role; active
RhoA promotes the assembly and contraction of actin filaments
within cells and leads to LATS2 inhibition and YAP/TAZ activa-
tion, whereas cells with reduced RhoA activity display LATS2
activation and inhibition of YAP/TAZ. Our data demonstrate
that a major defect in tetraploid cells is a significant reduction
in RhoA activity—the level of active RhoA in these cells is roughly
half of that observed in diploids, and increasing RhoA activity is
sufficient to rescue proliferation of tetraploid cells (Figures 4E
and 4H).
Several distinct, but not mutually exclusive, mechanisms may
explain the observed reduction of RhoA activity in tetraploid
cells. Centrosome amplification, one of the most obvious differ-
ences between diploid and tetraploid cells, is one contributing
factor. Centrosomes are microtubule nucleating and organizing
centers in cells, and tetraploids, with their doubled centrosome
content, exhibit increasedmicrotubule mass (Figure S5G), which
can have significant consequences on cellular physiology. For
example, consistent with prior work demonstrating that dynamicCell 158, 833–848, August 14, 2014 ª2014 Elsevier Inc. 843
AC
B
D E
Figure 6. Tetraploid Hepatocytes Activate the Hippo Pathway In Vivo
(A) Relative incorporation of EdU in 2N and 4N hepatocytes of wild-type mice as determined by FACS (n = 5; *p < 0.0005, one sample t test).
(B) Relative incorporation of EdU in 4N hepatocytes from p53+/+ and p53/ animals (n = 4; *p < 0.0005, unpaired t test).
(C) Western blot analysis of p53, p21, LATS2, and phosphorylated LATS2 protein levels in diploid (2N) and tetraploid (4N) hepatocytes isolated from the livers of
four wild-type mice. YAP phosphorylation was analyzed using PhosTag gels. Whole-liver extract (WLE) treated with l-phosphatase was used as control for
(legend continued on next page)
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microtubules stimulate the activity of the small G protein Rac1
(Godinho et al., 2014; Waterman-Storer et al., 1999), we find
that tetraploid cells display a nearly 2-fold increase in Rac1 activ-
ity relative to diploids (Figure 5A). Because active Rac1 in many
contexts can antagonize RhoA (Sander et al., 1999), increased
Rac1 activity provides one molecular explanation for the
observed loss of RhoA activity in tetraploids. In support of this
view, we find that inhibition of Rac activation is sufficient to
inhibit Hippo pathway signaling and to override the cell division
arrest of tetraploid cells (Figures 5B–5D); this also explains our
observation that centrosome amplification alone, in the absence
of tetraploidy, can trigger Hippo pathway activation (Figure 5E).
Recently, Holland et al. (2012) showed that centrosome amplifi-
cation leads to an elevation of p53 levels and a corresponding
decrease in the proliferation of nontransformed cells (Holland
et al., 2012); our data that the increase in p53 levels in such cells
is LATS2 dependent now provide a molecular underpinning for
this phenomenon. Moreover, we find that evolved tetraploid
RPE-1 cells, which adapt to silence Hippo signaling, consistently
lose their extra centrosomes (Ganem et al., 2009).
In addition to extra centrosomes, other scaling/cell-size ef-
fects associated with tetraploidy might contribute to reductions
in RhoA activity and Hippo pathway activation. For example,
tetraploid cells possess longer actin stress fibers, and the impact
of length changes on stress fiber function and mass are un-
known. Alternatively, the reduction in RhoA activity in tetraploids
may be an indirect consequence of a reduced surface area to
volume ratio, which may alter signaling from the plasma mem-
brane (such as from receptor tyrosine kinases and GPCRs),
which are important for RhoA activation and silencing of Hippo
signaling (Yin et al., 2013; Yu et al., 2012).
Hippo Pathway Inactivation in the Development of
High-Ploidy Tumors
An inference that can be drawn from this work is that the
development of high-ploidy tumors from spontaneously arising
tetraploid cells might commonly require inactivation of Hippo
pathway signaling. We previously demonstrated that tetraploid
p53/ mouse mammary epithelial cells that were transplanted
in nude mice rapidly developed into invasive cancers, whereas
isogenic diploids did not (Fujiwara et al., 2005). Array- compara-
tive genomic hybridization (CGH) analysis performed on ten of
these tetraploid-derived tumors revealed that all ten (derived
from five independent experiments) showed double minute
chromosomes with a recurrent amplicon of chromosome 9.
A similar amplicon has been identified in mouse and human
hepatocellular carcinomas, and YAP was identified as the major
oncogenic driver on this amplicon (Overholtzer et al., 2006; Zen-
der et al., 2006). We confirmed that all of the tetraploid-derived
tumors overexpressed YAP (Figure S7C). This suggests that,dephosphorylated YAP. The relative amounts of phosphorylated LATS2 and shift
right (n = 4; *p < 0.01, **p < 0.008, paired t test).
(D) Expression profiles of 2C and 4C hepatocytes, isolated from the livers of thre
gene-set signature (constructed as described in the Experimental Procedures).
(E) Constitutively active YAP (YAPS127A) was induced by doxycycline addition
YAP-expressing (YFP+) and YAP-non-expressing (YFP) hepatocytes was analy
All error bars represent mean ± SEM.although loss of p53 is sufficient to enable the initial proliferation
of tetraploid cells, Hippo pathway silencing and YAP activation is
likely required to sustain proliferation and promote tumorigen-
esis. Indeed, analysis of cell lines from the Cancer Cell Line
Encyclopedia shows that cancers of high-ploidy are significantly
more likely to amplify YAP and/or delete LATS1/2 than are near-
diploid cancers (Figures S7D–S7F).
YAP hyperactivation, p53 loss, and other tumor-promoting
mutations can arise from the massive genomic instability that
occurs in proliferating tetraploid cells. However, this raises a
paradox: how do tetraploid cells, which activate p53 through
Hippo pathway signaling and arrest the cell cycle, proliferate
initially to acquire the necessary oncogenic mutations required
for tumor development? Our data demonstrate that this can be
accomplished by subtly activating growth factor signaling, which
is sufficient to overcome tetraploid-induced cell-cycle arrest. We
have identified many known (IGFBP4) and perhaps uncharacter-
ized (PTBP1) negative regulators of growth factor signaling,
which represent potential tumor suppressors. One such regu-
lator, the serine protease inhibitor SPINT2, is a candidate tumor
suppressor that is silenced through DNAmethylation inmany hu-
man cancers (Nakamura et al., 2011). Bypassing physiologically
relevant low-level activation of the p53 pathway through repres-
sion of such genes may be of broad general relevance to tumor
initiation because numerous events that accompany onco-
genesis (e.g., oxidative stress, whole-chromosome aneuploidy,
and hypoxia) are known to initially trigger p53.EXPERIMENTAL PROCEDURES
Cell Culture, siRNA, and Imaging
RPE-1 cells were grown in DMEM:F12 media containing 10% FBS, 100 IU/ml
penicillin, and 100 mg/ml streptomycin. Cells were maintained at 37Cwith 5%
CO2 atmosphere. All siRNA transfections were performed using 50 nM siRNA
with Lipofectamine RNAi MAX. Fixed and live-cell imaging were performed as
described (Ganem et al., 2009). Complete details can be found in the Extended
Experimental Procedures.
Genome-wide RNAi Screening
Tetraploid RPE-1 FUCCI cells were generated by 16 hr of treatment with DCB,
isolated by FACS, and plated into 384-well screening dishes. Cells were
reverse transfected with pooled siRNAs targeting the human druggable
genome (Dharmacon). Fluorescent images were acquired after 96 hr to deter-
mine the fraction of proliferating tetraploid cells. The DNA damage screen was
similar in design except that cells were continuously treated with 40 ng/ml
doxorubicin. Complete screening details can be found in the Extended Exper-
imental Procedures.
Protein Extraction, Immunoprecipitation, and Immunoblotting
Cells were lysed in RIPA buffer, and protein was resolved using SDS-
PAGE. For immunoprecipitations, cells were lysed in NP-40 buffer, pre-
cleared with Protein A-sepharose and rabbit control antibody, and thened (above orange line) and hypershifted (above red line) YAP are quantified on
e different mice, were compared to a hepatocyte-specific Hippo-Off/Yap-On
in a subset of hepatocytes in the livers of 3-week-old mice. DNA content of
zed using FACS (n = 3; *p < 0.0005, unpaired t test).
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Figure 7. In Vitro Evolution to Generate Proliferating Tetraploid Cells
(A) Western blot analysis of YAP phosphorylation and p53 levels in evolved 4N RPE-1 cells relative to freshly generated 4N cells.
(B) GSEA analysis demonstrates that the expression of those genes identified from the RNAi screen is, as a whole, significantly reduced in the evolved tetraploids
(nominal p value < 0.01; FDR q value < 0.01).
(C) Expression of genes (uncovered by the RNAi screen) that are the most significantly repressed in the evolved tetraploids. Each column represents a technical
replicate. Red to blue coloring represents high to low gene expression.
(D) qPCR analysis of Hippo target genes in evolved tetraploids relative to freshly generated tetraploids (n = 3; *p < 0.05, unpaired t test). Error bars represent
mean ± SEM.
(legend continued on next page)
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immunoprecipitated with anti-HA sepharose for 4 hr at 4C. Phos-tag
gels were prepared and run according to the manufacturer’s instructions
(NARD).
RhoA and Rac1 Activation Assays
Diploid and tetraploid RPE-FUCCI cells were purified by FACS as described,
serum starved for 24 hr, and then stimulated with media containing 10%
serum for 6 hr. GTP-bound RhoA and Rac1 were immunoprecipitated
from diploid and tetraploid cells according to the manufacturers’ protocol
(Cytoskeleton).
hMSC Differentiation Assay
Diploid and tetraploid hMSCs (generated by 16 hr DCB treatment) were plated
at low densities on plastic dishes containing a 50:50mix of adipocyte and oste-
ogenic differentiation media. After 9–14 days, cells were fixed with paraformal-
dehyde and stained for adipocytes (oil red) and DNA (Hoechst).
Traction Force Microscopy
Diploid and tetraploid RPE-1 cells were plated on deformable poly-acrylamide
(PAA) hydrogels coated with fibronectin, and gel deformation was monitored
to measure the contractile forces produced. See Extended Experimental
Procedures for details.
Primary Hepatocyte Isolation and Hippo Inactivation In Vivo
Hepatocytes were collected from the livers of 3-week-old male C57BL/6 mice
(see Extended Experimental Procedures for details). For gene expression
profiling, hepatocytes were stained with Hoechst33342 (for DNA content)
and sorted by DNA content. To induce YAP S127A expression in vivo,
3-week-old tetracycline-inducible YAP S127A mice containing Rosa26-lox-
STOP-lox-rtTA and Rosa26-lox-STOP-lox-EYFP alleles were injected with
AAV8-TBG-Cre, and then doxycycline (1 mg/ml) was provided in the drinking
water after 7 days. Following 7 days of doxycycline treatment, hepatocytes
were isolated and analyzed for DNA content and YFP expression by FACS.
Antibodies, Plasmids, and siRNAs
A complete list of all antibodies, plasmids, qPCR, and siRNA sequences used
in this study can be found in the Extended Experimental Procedures.
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The GEO accession numbers for the microarray data reported in this paper are
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ploid hepatocytes).
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